Clinical trials: Recurrent IgA Nephropathy
Recurrent IgA Nephropathy
Rituximab in Recurrent IgA Nephropathy
Currently, the treatment options of recurrent IgA nephropathy (IgAN) are conflicting and largely based on expert opinions. Consequently, the recent KDIGO clinical practice guideline for the care of kidney transplant recipients…
- Trial name
- NCT02571842
- Testing
- Intravenous Rituximab, ACEI/ARB and corticosteroids
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Glomerulonephritis, IgAN
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment
IgA nephropathy (IgAN) is a histologically defined glomerulonephritis (renal biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at least 1+) by immunofluorescence.
- Trial name
- PIRAT (NCT02523768)
- Testing
- ATG-F, Simulect
- Where
- 15 sites in France
- Volunteers
- 117 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Immunoglobulin A Nephropathy, Kidney Diseases
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior…
- Conditions
- Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis
- Trial name
- SPARTAN (NCT04663204)
- Testing
- Sparsentan
- Where
- 6 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- University of Leicester